The briefing
A Phase 3 trial reported that setmelanotide significantly reduced body mass index and hunger in patients with acquired hypothalamic obesity. The findings point to a potential therapeutic option for a hard-to-treat condition.
Original headline
Setmelanotide Linked With Reduced BMI and Hunger in Patients With Acquired Hypothalamic Obesity